Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema — Stella

Home/Diabetic Macular Edema/

View on ClinicalTrials.gov

Recruiting

Back to Diabetic Macular Edema trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(1 site)

China

Peking Union Medical College Hospital, Beijing, Beijing Municipality

Key details

Phase

Large-scale testing

Sponsor

RemeGen Co., Ltd.

Enrollment target

~316 participants

Started

June 2023

Primary completion

June 2026

Age range

18 Years and older

Last updated September 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.